Early Morning Hearld

Small Cell Lung Cancer Pipeline Insights: Upcoming Therapies and Pharma Players Driving the SCLC Market Growth

 Breaking News
  • No posts were found

Small Cell Lung Cancer Pipeline Insights: Upcoming Therapies and Pharma Players Driving the SCLC Market Growth

July 30
15:08 2020
Small Cell Lung Cancer Pipeline Insights: Upcoming Therapies and Pharma Players Driving the SCLC Market Growth

Small Cell Lung Cancer Pipeline | SCLC Pipeline
Robust SCLC pipeline and increased healthcare spending are expected to change the dynamics of the ES-SCLC market.

Small Cell Lung Cancer Pipeline Insight, 2020’ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Small Cell Lung Cancer market.

 

Small Cell Lung Cancer (SCLC)- Disease Overview 

 

Small cell lung cancer (SCLC) or Small cell lung carcinoma is an aggressive and most malignant form of tumor, characterized by the uncontrolled, rapid growth of certain cells in the lungs. It accounts for almost 15% of all the lung cancers, the deadliest form of cancer in the world. 

The diagnosis of cancer mainly starts with a different set of tests that can be performed to examine cancer or for its better and effective treatment. 

 

Request for free sample pages: https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight

Small Cell Lung Cancer Marketed Therapies 

 

  • Opdivo (Nivolumab): Bristol-Myers Squibb

  • Keytruda (Pembrolizumab): Merck

 

Visit to read more: https://www.delveinsight.com/blog/small-cell-lung-cancer-market/

 

Small Cell Lung Cancer Pipeline Therapies 

 

  • Imfinzi +/- tremelimumab: AstraZeneca

  • RRx-001: EpicentRx

  • Lurbinectedin (PM01183): PharmaMar

 

Robust SCLC pipeline and increased healthcare spending are expected to change the dynamics of the ES-SCLC market.

 

Know more about report offerings: https://www.delveinsight.com/report-store/small-cell-lung-cancer-pipeline-insight

 

 A detailed picture of the Small Cell Lung Cancer pipeline landscape is provided, which includes the disease overview and Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces in-depth Small Cell Lung Cancer commercial assessment and clinical assessment of the Small Cell Lung Cancer pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Scope of the report

 

  • The Small Cell Lung Cancer report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Small Cell Lung Cancer across the complete product development cycle, including all clinical and nonclinical stages.

  • It comprises of detailed profiles of Small Cell Lung Cancer therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details

  • Detailed Small Cell Lung Cancer research and development progress and trial details, results wherever available, are also included in the pipeline study.

  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Small Cell Lung Cancer.

 

Table of Contents

1. Report Introduction

2. Small Cell Lung Cancer 

3. Small Cell Lung Cancer Current Treatment Patterns

4. Small Cell Lung Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Small Cell Lung Cancer Late Stage Products (Phase-III)

7. Small Cell Lung Cancer Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Small Cell Lung Cancer Discontinued Products

13. Small Cell Lung Cancer Product Profiles

14. Small Cell Lung Cancer Key Companies

15. Small Cell Lung Cancer Key Products

16. Dormant and Discontinued Products

17. Small Cell Lung Cancer Unmet Needs

18. Small Cell Lung Cancer Future Perspectives

19. Small Cell Lung Cancer Analyst Review  

20. Appendix

21. Report Methodology

 

Related Reports

Small Cell Lung Cancer- Market Insight, Epidemiology and Market Forecast -2030

DelveInsight’s ‘Small Cell Lung Cancer (SCLC)-Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the SCLC, historical and forecasted epidemiology as well as the SCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.  

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/